Sporotrichosis overview: Difference between revisions

Jump to navigation Jump to search
m (Changes made per Mahshid's request)
 
(3 intermediate revisions by 2 users not shown)
Line 2: Line 2:
{{Sporotrichosis}}
{{Sporotrichosis}}


{{CMG}}
{{CMG}}; {{AE}} {{AJL}}


==Overview==
==Overview==
'''Sporotrichosis''' (also known as "rose gardener's disease"<ref name="Bolognia">{{cite book |author=Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. |title=Dermatology: 2-Volume Set |publisher=Mosby |location=St. Louis |year=2007 |pages= |isbn=1-4160-2999-0 |oclc= |doi= |accessdate=}}</ref>) is a disease caused by an infection of the [[fungus]] ''[[Sporothrix schenckii]]''.<ref name="Sherris">{{cite book | author = Ryan KJ, Ray CG (editors) | title = Sherris Medical Microbiology | edition = 4th | pages = 654–6 | publisher = McGraw Hill | year = 2004 | isbn = 0-8385-8529-9 }}</ref>  This fungal disease usually affects the [[skin]], although other less common forms can affect the [[lung]]s, [[joint]]s, [[bone]]s, and even the [[brain]].  Because [[rose]]s can spread the disease, it is one of a few diseases referred to as ''rose-thorn'' or ''rose-gardeners' disease''.<ref>{{cite web | author = Volk T | title = ''Sporothrix schenckii'', cause of Rose-picker's Disease | work = Tom Volk's Fungus of the Month | url = http://botit.botany.wisc.edu/toms_fungi/feb2003.html | accessdate = 2007-06-16}}</ref>
'''Sporotrichosis''' (also known as "rose gardener's disease"<ref name="Bolognia">{{cite book |author=Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. |title=Dermatology: 2-Volume Set |publisher=Mosby |location=St. Louis |year=2007 |pages= |isbn=1-4160-2999-0 |oclc= |doi= |accessdate=}}</ref>) is a disease caused by an infection of the [[fungus]] ''[[Sporothrix schenckii]]''.<ref name="Sherris">{{cite book | author = Ryan KJ, Ray CG (editors) | title = Sherris Medical Microbiology | edition = 4th | pages = 654–6 | publisher = McGraw Hill | year = 2004 | isbn = 0-8385-8529-9 }}</ref>  This fungal disease usually affects the [[skin]], although other less common forms can affect the [[lung]]s, [[joint]]s, [[bone]]s, and even the [[brain]].  Because [[rose]]s can spread the disease, it is one of a few diseases referred to as ''rose-thorn'' or ''rose-gardeners' disease''.<ref>{{cite web | author = Volk T | title = ''Sporothrix schenckii'', cause of Rose-picker's Disease | work = Tom Volk's Fungus of the Month | url = http://botit.botany.wisc.edu/toms_fungi/feb2003.html | accessdate = 2007-06-16}}</ref>


Because ''S. schenckii'' is naturally found in soil, [[hay]], [[sphagnum moss]], and plants, it usually impacts [[farmer]]s, gardeners, and agricultural workers.<ref name="Sherris" /> Typically, infection manifests following the interruption of the epidermal integrity, as this allows the fungus to enter the host.  In cases where sporotrichosis impacts the lungs, known as pulmonary sporotrichosis, the fungal spores enter through the respiratory pathways upon inhalation. Zoonotic transmission of sporotrichosis occurs most frequently from handling infected cats, making this an occupational hazard for veterinarians.<ref name="pmid21976602">{{cite journal| author=Barros MB, de Almeida Paes R, Schubach AO| title=Sporothrix schenckii and Sporotrichosis. | journal=Clin Microbiol Rev | year= 2011 | volume= 24 | issue= 4 | pages= 633-54 | pmid=21976602 | doi=10.1128/CMR.00007-11 | pmc=PMC3194828 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21976602  }} </ref>
Because ''S. schenckii'' is naturally found in soil, [[hay]], sphagnum moss, and plants, it usually impacts farmers, gardeners, and agricultural workers.<ref name="Sherris" /> Typically, infection manifests following the interruption of the epidermal integrity, as this allows the [[fungus]] to enter the host.  In cases where sporotrichosis impacts the lungs, known as [[pulmonary]] sporotrichosis, the fungal spores enter through the [[respiratory]] pathways upon inhalation. [[Zoonotic]] transmission of sporotrichosis occurs most frequently from handling infected cats, making this an occupational hazard for veterinarians.<ref name="pmid21976602">{{cite journal| author=Barros MB, de Almeida Paes R, Schubach AO| title=Sporothrix schenckii and Sporotrichosis. | journal=Clin Microbiol Rev | year= 2011 | volume= 24 | issue= 4 | pages= 633-54 | pmid=21976602 | doi=10.1128/CMR.00007-11 | pmc=PMC3194828 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21976602  }} </ref>


Sporotrichosis progresses slowly - the first symptoms may appear 1 to 12 weeks (average 3 weeks) following initial exposure to ''S. schenckii'', and the patient may not recall the injury that led to infection. Serious complications can also arise in patients with compromised [[immune system]]<nowiki/>s. As systemic forms of sporotrichosis, also known as extracutaneous sporotrichosis, are opportunistic infections, immunocompromised patients are much more susceptible to these more severe subtypes.  
Sporotrichosis progresses slowly - the first symptoms may appear 1 to 12 weeks (average 3 weeks) following initial exposure to ''S. schenckii'', and the patient may not recall the injury that led to infection. Serious complications can also arise in patients with compromised [[immune system|immune system<nowiki/>s]]. As systemic forms of sporotrichosis, also known as extracutaneous sporotrichosis, are [[Opportunistic infection|opportunistic infections]], [[Immunodeficiency|immunocompromised]] patients are much more susceptible to these more severe subtypes.
==Historical Perspective==
The first definitive case of sporotrichosis was described by Benjamin Schenck, an American medical student, in 1896.
==Classification==
Sporotrichosis may be classified, according to the location of the lesions, into particular subtypes: fixed cutaneous, lymphocutaneous, disseminated cutaneous, and extracutaneous/systemic. These subtypes may be further separated into increasingly specific forms based upon clinical manifestations.


==Pathophysiology==
''S. schenckii'' is usually transmitted via posttraumatic inoculation to the human host, however, infrequently sporotrichosis may also develop as a result of spore inhalation. The pathophysiology of sporotrichosis depends on the histological subtype and the frequently nonspecific histopathology may mimic other granulomatous diseases.<ref name="pmid25614735">{{cite journal| author=Mahajan VK| title=Sporotrichosis: an overview and therapeutic options. | journal=Dermatol Res Pract | year= 2014 | volume= 2014 | issue=  | pages= 272376 | pmid=25614735 | doi=10.1155/2014/272376 | pmc=PMC4295339 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25614735  }} </ref> ''S. schenckii'' is capable of modulating the immune response to promote its own survival by blocking cytokine production by [[macrophages]].<ref name="Carlos">{{cite journal |author=Carlos IZ, Sassá MF, da Graça Sgarbi DB, Placeres MC, Maia DC |title=Current research on the immune response to experimental sporotrichosis |journal=Mycopathologia |volume=168 |issue=1 |pages=1–10 |date=July 2009 |pmid=19241140 |doi=10.1007/s11046-009-9190-z}}</ref>
==Causes==
Sporothrix schenckii is a fungus that can be found throughout the world. Areas characterized by warm, humid climates, are ideal for the fungus to thrive. The species is present in soil as well as in and on living and decomposing plant material such as peat moss. It can infect humans as well as animals and is the causative agent of sporotrichosis, commonly known as "rose handler's disease".
==Differential Diagnosis==
As sporotrichosis manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype. Forms of cutaneous sporotrichosis must be differentiated from other diseases that cause [[lesions]], such as [[cutaneous leishmaniasis]] and mycobacteriosis, while the various forms of extracutaneous sporotrichosis must be differentiated from other diseases with similar clinical manifestations. For example, pulmonary sporotrichosis must be differentiated from other diseases that attack the lungs, such as [[coccidioidomycosis]] and [[histoplasmosis]], whereas osteoarticular sporotrichosis must be distinguished from diseases that affect the bones and joints, such as chronic bacterial [[osteomyelitis]].
==Epidemiology and Demographics==
''Sporothrix schenckii'' can be found throughout the world in soil and plant matter. Peru is suspected to be an area where ''S. schenckii'' is extremely common in the environment. Outbreaks of sporotrichosis have been documented in both developing and developed countries.
==Risk Factors==
The most potent risk factor in the development of sporotrichosis is handling thorny plants, sphagnum moss, bales of hay, or any plant or plant product that can cause skin trauma. These risk factors either lead to direct [[inoculation]] or merely enable the entry of the [[fungus]]. Other risk factors include a [[Immunodeficiency|weakened immune system]], a history of [[alcoholism]], and the handling of infected animals.  <ref name="CDCrisk">{{cite web |url=http://www.cdc.gov/fungal/diseases/sporotrichosis/risk-prevention.html|title=Risk and Prevention|date=2015|website=CDC.Gov|publisher=Center for Disease Control |access-date=January 5, 2015 |quote=}}</ref>
==Natural History, Complications and Prognosis==
The incubation period of sporotrichosis varies from a few days to multiple months. <ref name="incubationspor">Vásquez-del-Mercado E, Arenas R, Padilla-Desgarenes C. Sporotrichosis. Clinics in Dermatology. 2012;30(4):437-443. doi:10.1016/j.clindermatol.2011.09.017.</ref> Complicatiaons of sporotrichosis include bacterial superinfection and sepsis. Depending on the progression of the sporotrichosis at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as good. The presence of disseminated sporotrichosis is associated with a particularly poor prognosis among [[Immunodeficiency|immunodeficient]] patients and these patients are prone to relapse.
==Diagnosis==
===History and Symptoms===
Symptoms of cutaneous sporotrichosis include [[nodular lesions]] on the skin, at the point of [[inoculation]], as well as along [[lymph]] nodes and vessels. The [[lesion]] is initially small and painless, and ranges in color from pink to purple.  Left untreated, the [[lesion]] becomes larger, [[Ulcerated lesion|ulcerates]], and oozes. Typically, cutaneous sporotrichosis [[Lesion|lesions]] manifest in the upper extremities. Extracutaneous forms of sporotrichosis typically manifest with a broad range of unspecific clinical symptoms, frequently resulting in delayed diagnosis.
===Physical Examination===
Common physical examination findings of cutaneous sporotrichosis include painless pink to purple [[nodular lesions]] or [[erythematous]] [[plaque]] on the skin, which may begin to grow, ulcerate, and drain. These [[Lesion|lesions]] characteristically manifest on upper extremities. Non-cutaneous forms of sporotrichosis are not generally associated with distinctive physical findings.
===Laboratory Findings===
Laboratory findings consistent with the diagnosis of sporotrichosis include isolation of ''S. schenckii'' upon culture, molecular detection, a positive sporotrichin skin test, and techniques involving [[Antibody microarray|antibody detection]]. Definitive diagnosis of sporotrichosis occurs upon the isolation and identification of ''S. schenckii'' in culture.
===Chest X Ray===
Findings suggestive of sporotrichosis on chest x-ray include the presence of cavitations, tracheobronchial lymph node enlargement, and presence of nodular lesions.
==Treatment==
===Medical Therapy===
Because spontaneous resolution in cases of sporotrichosis is a rarity, the majority of patients require treatment. The recommended treatment regimens are largely empirical and predominantly based upon retrospective evaluations, case study reports, and nonrandomized control trials. The predominant therapy for sporotrichosis is [[itraconazole]], which is used as the primary treatment in [[immunocompetent]] patients, and as a suppressive therapy in [[Immunocompromised host|immunocompromised patients]]. The primary line of treatment for  [[Immunocompromised host|immunocompromised patients]] is [[amphotericin B]].
===Surgery===
[[Surgery]] is not the first­ line treatment option for patients with cutaneous sporotrichosis. [[Surgery|Surgical]] therapy is usually reserved for patients with either osteoarticular sporotrichosis or pulmonary sporotrichosis.
===Prevention===
There are no available [[Vaccine|vaccines]] against sporotrichosis. Primary prevention strategies include wearing protective clothing while engaging in high [[Sporotrichosis risk factors|risk]] activities, such as handling thorny plants, sphagnum moss, bales of hay, or any plant or plant product that may potentially cause skin trauma, limiting handling of sphagnum moss, and avoiding physical contact with infected animals, namely felines.
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}


[[Category:Disease]]
[[Category:Disease]]
[[Category:Infectious disease]]

Latest revision as of 19:07, 18 September 2017

Sporotrichosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Sporotrichosis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

Treatment

Medical Therapy

Surgery

Prevention

Case Studies

Case #1

Sporotrichosis overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sporotrichosis overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sporotrichosis overview

CDC on Sporotrichosis overview

Sporotrichosis overview in the news

Blogs on Sporotrichosis overview

Directions to Hospitals Treating Sporotrichosis

Risk calculators and risk factors for Sporotrichosis overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alison Leibowitz [2]

Overview

Sporotrichosis (also known as "rose gardener's disease"[1]) is a disease caused by an infection of the fungus Sporothrix schenckii.[2] This fungal disease usually affects the skin, although other less common forms can affect the lungs, joints, bones, and even the brain. Because roses can spread the disease, it is one of a few diseases referred to as rose-thorn or rose-gardeners' disease.[3]

Because S. schenckii is naturally found in soil, hay, sphagnum moss, and plants, it usually impacts farmers, gardeners, and agricultural workers.[2] Typically, infection manifests following the interruption of the epidermal integrity, as this allows the fungus to enter the host. In cases where sporotrichosis impacts the lungs, known as pulmonary sporotrichosis, the fungal spores enter through the respiratory pathways upon inhalation. Zoonotic transmission of sporotrichosis occurs most frequently from handling infected cats, making this an occupational hazard for veterinarians.[4]

Sporotrichosis progresses slowly - the first symptoms may appear 1 to 12 weeks (average 3 weeks) following initial exposure to S. schenckii, and the patient may not recall the injury that led to infection. Serious complications can also arise in patients with compromised immune systems. As systemic forms of sporotrichosis, also known as extracutaneous sporotrichosis, are opportunistic infections, immunocompromised patients are much more susceptible to these more severe subtypes.

Historical Perspective

The first definitive case of sporotrichosis was described by Benjamin Schenck, an American medical student, in 1896.

Classification

Sporotrichosis may be classified, according to the location of the lesions, into particular subtypes: fixed cutaneous, lymphocutaneous, disseminated cutaneous, and extracutaneous/systemic. These subtypes may be further separated into increasingly specific forms based upon clinical manifestations.

Pathophysiology

S. schenckii is usually transmitted via posttraumatic inoculation to the human host, however, infrequently sporotrichosis may also develop as a result of spore inhalation. The pathophysiology of sporotrichosis depends on the histological subtype and the frequently nonspecific histopathology may mimic other granulomatous diseases.[5] S. schenckii is capable of modulating the immune response to promote its own survival by blocking cytokine production by macrophages.[6]

Causes

Sporothrix schenckii is a fungus that can be found throughout the world. Areas characterized by warm, humid climates, are ideal for the fungus to thrive. The species is present in soil as well as in and on living and decomposing plant material such as peat moss. It can infect humans as well as animals and is the causative agent of sporotrichosis, commonly known as "rose handler's disease".

Differential Diagnosis

As sporotrichosis manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype. Forms of cutaneous sporotrichosis must be differentiated from other diseases that cause lesions, such as cutaneous leishmaniasis and mycobacteriosis, while the various forms of extracutaneous sporotrichosis must be differentiated from other diseases with similar clinical manifestations. For example, pulmonary sporotrichosis must be differentiated from other diseases that attack the lungs, such as coccidioidomycosis and histoplasmosis, whereas osteoarticular sporotrichosis must be distinguished from diseases that affect the bones and joints, such as chronic bacterial osteomyelitis.

Epidemiology and Demographics

Sporothrix schenckii can be found throughout the world in soil and plant matter. Peru is suspected to be an area where S. schenckii is extremely common in the environment. Outbreaks of sporotrichosis have been documented in both developing and developed countries.

Risk Factors

The most potent risk factor in the development of sporotrichosis is handling thorny plants, sphagnum moss, bales of hay, or any plant or plant product that can cause skin trauma. These risk factors either lead to direct inoculation or merely enable the entry of the fungus. Other risk factors include a weakened immune system, a history of alcoholism, and the handling of infected animals. [7]

Natural History, Complications and Prognosis

The incubation period of sporotrichosis varies from a few days to multiple months. [8] Complicatiaons of sporotrichosis include bacterial superinfection and sepsis. Depending on the progression of the sporotrichosis at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as good. The presence of disseminated sporotrichosis is associated with a particularly poor prognosis among immunodeficient patients and these patients are prone to relapse.

Diagnosis

History and Symptoms

Symptoms of cutaneous sporotrichosis include nodular lesions on the skin, at the point of inoculation, as well as along lymph nodes and vessels. The lesion is initially small and painless, and ranges in color from pink to purple. Left untreated, the lesion becomes larger, ulcerates, and oozes. Typically, cutaneous sporotrichosis lesions manifest in the upper extremities. Extracutaneous forms of sporotrichosis typically manifest with a broad range of unspecific clinical symptoms, frequently resulting in delayed diagnosis.

Physical Examination

Common physical examination findings of cutaneous sporotrichosis include painless pink to purple nodular lesions or erythematous plaque on the skin, which may begin to grow, ulcerate, and drain. These lesions characteristically manifest on upper extremities. Non-cutaneous forms of sporotrichosis are not generally associated with distinctive physical findings.

Laboratory Findings

Laboratory findings consistent with the diagnosis of sporotrichosis include isolation of S. schenckii upon culture, molecular detection, a positive sporotrichin skin test, and techniques involving antibody detection. Definitive diagnosis of sporotrichosis occurs upon the isolation and identification of S. schenckii in culture.

Chest X Ray

Findings suggestive of sporotrichosis on chest x-ray include the presence of cavitations, tracheobronchial lymph node enlargement, and presence of nodular lesions.

Treatment

Medical Therapy

Because spontaneous resolution in cases of sporotrichosis is a rarity, the majority of patients require treatment. The recommended treatment regimens are largely empirical and predominantly based upon retrospective evaluations, case study reports, and nonrandomized control trials. The predominant therapy for sporotrichosis is itraconazole, which is used as the primary treatment in immunocompetent patients, and as a suppressive therapy in immunocompromised patients. The primary line of treatment for immunocompromised patients is amphotericin B.

Surgery

Surgery is not the first­ line treatment option for patients with cutaneous sporotrichosis. Surgical therapy is usually reserved for patients with either osteoarticular sporotrichosis or pulmonary sporotrichosis.

Prevention

There are no available vaccines against sporotrichosis. Primary prevention strategies include wearing protective clothing while engaging in high risk activities, such as handling thorny plants, sphagnum moss, bales of hay, or any plant or plant product that may potentially cause skin trauma, limiting handling of sphagnum moss, and avoiding physical contact with infected animals, namely felines.

References

  1. Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. ISBN 1-4160-2999-0.
  2. 2.0 2.1 Ryan KJ, Ray CG (editors) (2004). Sherris Medical Microbiology (4th ed.). McGraw Hill. pp. 654–6. ISBN 0-8385-8529-9.
  3. Volk T. "Sporothrix schenckii, cause of Rose-picker's Disease". Tom Volk's Fungus of the Month. Retrieved 2007-06-16.
  4. Barros MB, de Almeida Paes R, Schubach AO (2011). "Sporothrix schenckii and Sporotrichosis". Clin Microbiol Rev. 24 (4): 633–54. doi:10.1128/CMR.00007-11. PMC 3194828. PMID 21976602.
  5. Mahajan VK (2014). "Sporotrichosis: an overview and therapeutic options". Dermatol Res Pract. 2014: 272376. doi:10.1155/2014/272376. PMC 4295339. PMID 25614735.
  6. Carlos IZ, Sassá MF, da Graça Sgarbi DB, Placeres MC, Maia DC (July 2009). "Current research on the immune response to experimental sporotrichosis". Mycopathologia. 168 (1): 1–10. doi:10.1007/s11046-009-9190-z. PMID 19241140.
  7. "Risk and Prevention". CDC.Gov. Center for Disease Control. 2015. Retrieved January 5, 2015.
  8. Vásquez-del-Mercado E, Arenas R, Padilla-Desgarenes C. Sporotrichosis. Clinics in Dermatology. 2012;30(4):437-443. doi:10.1016/j.clindermatol.2011.09.017.